fda compounding semaglutide crackdown 2025 news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compounded GLP-1s: Why doctors worry

Indeed, GCLC has non-canonical functions in sequestering glutamate levels to prevent ferroptosis 51

The Cosmo Glutathione Body Serum-In Lotion is designed to help improve the look of dull skin while delivering long-lasting hydration

Compounding of semaglutide will continue until at least May 22, 2025, for 503B Pharmacies (also known as 503B Outsourcing Facilities, which are compounding pharmacies that can produce large batches of medications without patient-specific prescriptions)

Favorable Safety Profile: Unlike full growth hormone therapy, AOD-9604 does not stimulate IGF-1 production or affect glucose metabolism

As 2025 ended, the Trump administration announced that it would seek to lower costs and increase access to GLP-1s for Medicare and Medicaid recipients

Dancing With The Stars Couple Confirms Relationship Its a match made in ballroom heaven